Purity matters: multifunctional roles of L-Arginine and L-Histidine in bioprocessing and formulation

Introduction: L-arginine and L-histidine are critical in manufacturing monoclonal antibodies, cytokines, and other immunotherapy biologics.Beyond metabolic and buffering roles, they modulate conformational stability, aggregation, viscosity, and excipient compatibility.Trace transition metals (like Fe, Cu, Co) catalyze oxidative pathways, drive polysorbate degradation, and promote high-molecular-weight aggregates-key risks where potency and structure affect immune function.Thus, amino acid purity and trace-metal control are pivotal across upstream, downstream, and formulation stages.Objectives: To define how L-arginine and L-histidine (and hydrochloride salts) affect upstream cell performance, downstream recovery, and formulation stability of antibody-based immunotherapies, emphasizing chemical purity and trace-metal burden.Methodology: CHO suspension cells were subjected to arginine/histidine depletion or supplementation; viability and cell density were quantified.Downstream work compared Protein A elution using argininebased versus citrate buffers and evaluated aggregate resolution by SEC-HPLC.Formulation studies tested histidine-polysorbate compatibility under oxidative stress and quantified arginine's viscosity reduction in >100 mg/mL immunoglobulin.Trace-metal levels were measured and correlated with stability outcomes.Results: Depletion caused severe viability loss (95% viability and supported densities >8 10 6 cells/mL, enabling high-intensity production.Argininebased elution at pH 4.4 improved recovery versus citrate at equal pH and reduced acid-induced stress.Arginine in SEC-HPLC mobile phases enhanced the resolution of high-molecular-weight aggregates.Histidine buffers with low metal/peroxide loads mitigated polysorbate oxidation.Arginine reduced the viscosity from >30 cP to ~13 cP in concentrated antibodies. Conclusion:L-arginine and L-histidine act as multifunctional excipients that improve cellular productivity, stabilize proteins during purification, and enhance manufacturability and delivery of high-concentration immunotherapies.Their impact is governed by chemical purity and trace-metal control, which directly modulate oxidative pathways, aggregation, and excipient compatibility.Prioritizing excipient quality is essential for stable, scalable, patient-friendly immunotherapy products.